RELAPSE MULTIPLE MYELOMA
Clinical trials for RELAPSE MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSE MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSE MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tame Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive a drug called talquetamab to help control the cancer, followed by a one-time infusion of their own modified immune cells (ci…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New hope for hard-to-treat myeloma: drug combo shows promise in phase 2 trial
Disease control Recruiting nowThis study is for people with multiple myeloma that has returned or is no longer responding to standard treatments, including CAR T-cell therapy. Researchers are testing a combination of four drugs (belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone) to see if it …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 17, 2026 00:29 UTC
-
Can a Follow-Up drug stop myeloma relapse after CAR t?
Disease control Recruiting nowThis study tests whether the drug elranatamab, given after CAR T-cell therapy (idecabtagene vicleucel), can lower the chance of multiple myeloma worsening. It enrolls 32 adults with relapsed or refractory multiple myeloma. The goal is to see if this combination improves response …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug cocktail aims to control relapsed blood cancer
Disease control Recruiting nowThis study tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see how well the combination controls the cancer. About 62 ad…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Natalie Callander • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New vaccine boosts CAR-T power against tough blood cancer
Disease control Recruiting nowThis early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy is safe and works better for people with multiple myeloma that has come back or not responded to treatment. About 25 adults will receive the vaccine along with …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Double-targeted cell therapy takes on hard-to-treat myeloma
Disease control Recruiting nowThis study is testing a new treatment called CD19/BCMA CAR-T cell therapy for people with multiple myeloma that has returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins (CD19 and BCMA) on myeloma cel…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Custom-Made vaccine trial offers new hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing whether a personalized cancer vaccine made from a patient's own cells, when combined with an immunotherapy drug called elranatamab, is safe and effective for treating multiple myeloma that has returned or stopped responding to standard treatments…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New study aims to stop bitter side effect of myeloma drug
Symptom relief Recruiting nowThis study tests if certain preventive treatments can reduce or prevent taste changes caused by a multiple myeloma drug called talquetamab. About 210 people with multiple myeloma will be randomly assigned to different preventive strategies. The goal is to improve quality of life …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated May 14, 2026 12:03 UTC